Trials / Completed
CompletedNCT01169363
Biomarkers in Bone Marrow and Blood Samples From Older Patients With Acute Myeloid Leukemia Treated With Cytarabine-Based Therapy
Validation of AML Proteomic Signature Associated With Clinical Response to Ara-C Based Induction Therapy in Patients 60 Years of Age or Older Using Samples From ECOG Studies 3999, 3993 and 1490
- Status
- Completed
- Phase
- —
- Study type
- Observational
- Enrollment
- 200 (actual)
- Sponsor
- ECOG-ACRIN Cancer Research Group · Network
- Sex
- All
- Age
- 60 Years – 120 Years
- Healthy volunteers
- Not accepted
Summary
RATIONALE: Studying samples of bone marrow and blood from patients with cancer in the laboratory may help doctors predict how well patients will respond to treatment. PURPOSE: This research study is studying biomarkers in bone marrow and blood samples from older patients with acute myeloid leukemia treated with cytarabine-based therapy.
Detailed description
OBJECTIVES: Primary * To validate a pre-specified proteomic classifier to predict the likelihood of complete response (CR) to cytarabine-based induction chemotherapy in older patients with non-M3 acute myeloid leukemia. Secondary * To identify signaling nodes associated with risk of relapse among these patients who achieve a CR to induction chemotherapy. OUTLINE: This is a multicenter study. Previously collected bone marrow and peripheral blood samples are analyzed to validate the association of a pre-specified proteomic signature with clinical response via flow cytometry.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| GENETIC | proteomic profiling | |
| OTHER | flow cytometry | |
| OTHER | laboratory biomarker analysis |
Timeline
- Start date
- 2010-07-08
- Primary completion
- 2010-08-08
- Completion
- 2010-08-08
- First posted
- 2010-07-26
- Last updated
- 2017-05-17
Source: ClinicalTrials.gov record NCT01169363. Inclusion in this directory is not an endorsement.